Last reviewed · How we verify
Rosuvastatin-ranitidine
Rosuvastatin-ranitidine is a Fixed-dose combination: HMG-CoA reductase inhibitor + H2-receptor antagonist Small molecule drug developed by Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec. It is currently FDA-approved for Hypercholesterolemia with gastrointestinal intolerance or risk.
This is a fixed-dose combination of rosuvastatin (a statin that lowers cholesterol) and ranitidine (an H2-receptor antagonist that reduces stomach acid).
Rosuvastatin is a statin used to treat coronary artery disease, and it is often combined with other medications. Ranitidine, a histamine H2 receptor antagonist, is a small molecule that works by blocking the histamine H2 receptor, which is involved in stomach acid production.
At a glance
| Generic name | Rosuvastatin-ranitidine |
|---|---|
| Sponsor | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec |
| Drug class | Fixed-dose combination: HMG-CoA reductase inhibitor + H2-receptor antagonist |
| Target | HMG-CoA reductase (rosuvastatin component); Histamine H2 receptor (ranitidine component) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Rosuvastatin inhibits HMG-CoA reductase to reduce LDL cholesterol and cardiovascular risk, while ranitidine blocks histamine H2 receptors on gastric parietal cells to reduce acid secretion. The combination is designed to provide cardiovascular protection while mitigating gastrointestinal side effects that may occur with statin monotherapy.
Approved indications
- Hypercholesterolemia with gastrointestinal intolerance or risk
Common side effects
- Headache
- Myalgia
- Gastrointestinal upset
- Elevated liver enzymes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rosuvastatin-ranitidine CI brief — competitive landscape report
- Rosuvastatin-ranitidine updates RSS · CI watch RSS
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec portfolio CI
Frequently asked questions about Rosuvastatin-ranitidine
What is Rosuvastatin-ranitidine?
How does Rosuvastatin-ranitidine work?
What is Rosuvastatin-ranitidine used for?
Who makes Rosuvastatin-ranitidine?
What drug class is Rosuvastatin-ranitidine in?
What development phase is Rosuvastatin-ranitidine in?
What are the side effects of Rosuvastatin-ranitidine?
What does Rosuvastatin-ranitidine target?
Related
- Drug class: All Fixed-dose combination: HMG-CoA reductase inhibitor + H2-receptor antagonist drugs
- Target: All drugs targeting HMG-CoA reductase (rosuvastatin component); Histamine H2 receptor (ranitidine component)
- Manufacturer: Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypercholesterolemia with gastrointestinal intolerance or risk
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing